Ghadimi Mahnaz, Foroughi Farshad, Hashemipour Sima, Nooshabadi Mohammadreza Rashidi, Ahmadi Mohammad Hossein, Yari Mojtaba Ghadimi, Kavianpour Maria, Haghighian Hossein Khadem
Department of Nutrition, School of Health, Qazvin University of Medical Sciences, Qazvin, Iran.
Department of Immunology, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran.
Diabetol Metab Syndr. 2021 Feb 5;13(1):16. doi: 10.1186/s13098-021-00633-8.
The beneficial effects of polyphenols have been reported. This study aimed to investigate the effect of oral Ellagic acid (EA) supplement on insulin resistance (IR) and Fetuin-A and serum sirtuin1 (SIRT1) in type 2 diabetics.
In this double-blind, randomized clinical trial, 44 diabetic patients were selected. Patients were assigned to the intervention group (22 subjects) and placebo (22 subjects) and received a capsule containing 180 mg of EA per day or placebo for eight weeks, respectively. At the beginning and end of the study, anthropometric indices, fasting plasma glucose (FPG), plasma insulin level, IR, Fetuin-A, and SIRT1 were measured. Statistical analysis was performed using SPSS software.
At the beginning and end of the study, there was no significant difference between the two groups regarding anthropometric indices (P > 0.05). At the end of the survey, EA supplementation significantly reduced FPG, insulin, IR, and Fetuin-A and increased SIRT1 levels compared with the placebo group (P < 0.05). However, these changes were not significant in the placebo group (P > 0.05).
EA with antioxidant properties plays an essential role in reducing the macrovascular and microvascular complications of diabetes by reducing inflammation and insulin resistance. Trial registration The protocol of this clinical trial is registered with the Iranian Registry of Clinical Trials ( http://www.IRCT.IR , identifier: IRCT20141025019669N13).
已有报道称多酚具有有益作用。本研究旨在探讨口服鞣花酸（EA）补充剂对2型糖尿病患者胰岛素抵抗（IR）、胎球蛋白-A和血清沉默信息调节因子1（SIRT1）的影响。
在这项双盲、随机临床试验中，选取了44例糖尿病患者。将患者分为干预组（22例受试者）和安慰剂组（22例受试者），分别接受每天一粒含180毫克EA的胶囊或安慰剂，持续八周。在研究开始和结束时，测量人体测量指标、空腹血糖（FPG）、血浆胰岛素水平、IR、胎球蛋白-A和SIRT1。使用SPSS软件进行统计分析。
在研究开始和结束时，两组在人体测量指标方面无显著差异（P＞0.05）。在调查结束时，与安慰剂组相比，补充EA显著降低了FPG、胰岛素、IR和胎球蛋白-A，并提高了SIRT1水平（P＜0.05）。然而，这些变化在安慰剂组中并不显著（P＞0.05）。
具有抗氧化特性的EA通过减轻炎症和胰岛素抵抗，在减少糖尿病的大血管和微血管并发症方面发挥着重要作用。试验注册 本临床试验方案已在伊朗临床试验注册中心注册（http://www.IRCT.IR，标识符：IRCT20141025019669N13）。
